Core Insights - Cabaletta Bio is focused on developing and commercializing rese-cel, a product aimed at redefining the treatment of autoimmune diseases [3]. Company Overview - The company was founded with the intention of replicating successful academic studies conducted by Professor Schett, which demonstrated promising results in treating autoimmune diseases [3]. - The design of rese-cel closely mirrors the product used in academic studies, with dosing adjusted based on weight to align with clinical data [3]. Development Timeline - The timeline for the development of rese-cel includes an IND filing in 2023, with expectations to address multiple diseases by the end of 2025 [4].